{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-23-000326","form_type":"8-K","ticker":"CDIO","cik":"0001870144","company_name":"Cardio Diagnostics Holdings, Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.287503+00:00","generated_at":"2026-06-18T04:55:59.923210+00:00","sec_items":["1.01","2.03","3.02","7.01","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cardio Diagnostics enters $11.2M convertible debenture financing with Yorkville; receives initial $4.5M","bullets":["Gross proceeds up to $11.2M from YA II PN, Ltd. (Yorkville); first tranche $5M debenture at 90% ($4.5M), second $6.2M upon SEC reg. effectiveness.","Convertible at lower of $5.00 or 92% of avg two lowest daily VWAPs over 7 days, floor $0.55; 12-month maturity, 0% interest (15% on default).","Proceeds to expand commercial adoption of PrecisionCHD and Epi+Gen CHD tests, launch new cardiovascular tests, and pursue payor coverage.","Company has no deposits at Silicon Valley Bank; all deposits except <$250K in a major money center bank."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-23-000326","json":"https://secwatch.observer/filing/0001079973-23-000326.json","markdown":"https://secwatch.observer/filing/0001079973-23-000326.md","text":"https://secwatch.observer/filing/0001079973-23-000326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870144/000107997323000326/0001079973-23-000326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870144/000107997323000326/cdio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:55:59.923210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed565d9005cac1a413c6f38ef03de74d9097049b","claim":"Cardio Diagnostics Holdings, Inc. incurred convertible notes of principal amount of $5 million with YA II PN, Ltd. (Yorkville) at 0.0% per annum maturing March 8, 2024.","evidence_excerpt":"the Company issued and sold to Yorkville a Convertible Debenture in the principal amount of $5 million for a purchase price of $4.5 million","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870144/000107997323000326/0001079973-23-000326-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"principal amount of $5 million"},{"label":"Counterparty","value":"YA II PN, Ltd. (Yorkville)"},{"label":"Rate","value":"0.0% per annum"},{"label":"Maturity","value":"March 8, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"4bb2f1838dd7ced17bdc5950535b53df79545a31","claim":"Cardio Diagnostics Holdings, Inc. entered into Securities Purchase Agreement with YA II PN, Ltd. (Yorkville) valued at up to $11.2 million (effective 2023-03-08).","evidence_excerpt":"On March 8, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with YA II PN, Ltd. (“Yorkville”), a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870144/000107997323000326/0001079973-23-000326-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"YA II PN, Ltd. (Yorkville)"},{"label":"Value","value":"up to $11.2 million"},{"label":"Effective","value":"2023-03-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}